Home › Trials › NCT04912401

Evaluating Etanercept for treating moderate-to-severe psoriasis in Chinese patients

A Prospective Study With Induction Dosing Period Followed by a Maintenance Dosing Period to Evaluate the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis

Observational Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT04912401

This study is testing if the medication Etanercept can help Chinese patients aged 18 to 75 with moderate-to-severe psoriasis feel better and improve their skin over time.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University Academic / other
Locations40 sites (Hangzhou, Zhejiang and 39 other locations)
Trial IDNCT04912401 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the efficacy and safety of Etanercept in patients with moderate-to-severe chronic psoriasis. It is a prospective, open-label, one-arm study designed to gather real-world data that can guide clinical practice. Eligible participants will be those aged 18 to 75 with a significant psoriasis burden, and the study will monitor their response to Etanercept therapy over time.

Who should consider this trial

Good fit: Ideal candidates are Chinese patients aged 18 to 75 with moderate to severe chronic psoriasis who are candidates for systemic therapy or phototherapy.

Not a fit: Patients with pustular psoriasis, erythroderma psoriasis, or those with severe infections may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide effective treatment options for patients suffering from moderate-to-severe psoriasis.

How similar studies have performed: Other studies have shown positive outcomes with Etanercept in treating psoriasis, indicating that this approach is supported by existing evidence.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy or phototherapy 5.No contradiction to Etanercept 6.Informed consent must be obtained 7.For female, ß-hCG test is negative and contraception is accepted

Exclusion Criteria:

1. Diagnosis of pustular psoriasis, erythroderma psoriasis or drug-induced psoriasis
2. Having severe infections, including hepatitis, HIV and tuberculosis
3. No live vaccines 12 weeks before enrollment, through the study and 1 year after the last dose of Etanercept
4. Having significant allergies to biological agents
5. Having the previous experience of biologics
6. Having a history of malignancy
7. Having contradictions to Etanercept
8. Refusal of contraception
9. Having serious or unstable/uncontrolled illnesses

Where this trial is running

Hangzhou, Zhejiang and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions PsoriasisEtanercept
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.